Pazopanib
CAS No. 444731-52-6
Pazopanib ( GW-786034B;GW-786034;GW786034 )
产品货号. M14522 CAS No. 444731-52-6
A potent, orally available, pan-VEGFR inhibitor with IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
10MG | ¥340 | 有现货 |
|
25MG | ¥543 | 有现货 |
|
50MG | ¥786 | 有现货 |
|
100MG | ¥1199 | 有现货 |
|
200MG | ¥2017 | 有现货 |
|
500MG | ¥2827 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Pazopanib
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述A potent, orally available, pan-VEGFR inhibitor with IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively.
-
产品描述A potent, orally available, pan-VEGFR inhibitor with IC50 of 10, 30, and 47 nM for VEGFR-1, -2, and -3, respectively; also shows significant activity against the closely related RTKs PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50 of 84, 74, 140, and 146 nM, respectively; potently inhibits VEGF-induced phosphorylation of VEGFR-2 in HUVEC cells with IC50 of 8 nM; inhibits in vivo tumor growth, increases MM cell apoptosis, decreases angiogenesis, and prolongs host survival in a xenograft model of human MM. Kidney Cancer Approved
-
同义词GW-786034B;GW-786034;GW786034
-
通路Angiogenesis
-
靶点VEGFR
-
受体c-Kit;PDGFR;VEGFR1;VEGFR2;VEGFR3
-
研究领域Cancer
-
适应症Kidney Cancer
化学信息
-
CAS Number444731-52-6
-
分子量437.52
-
分子式C21H23N7O2S
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 43 mg/mL
-
SMILESO=S(C1=CC(NC2=NC=CC(N(C3=CC4=NN(C)C(C)=C4C=C3)C)=N2)=CC=C1C)(N)=O
-
化学全称Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
2. Kumar R, et al. Mol Cancer Ther. 2007 Jul;6(7):2012-21.
3. Harris PA, et al. J Med Chem. 2008 Aug 14;51(15):4632-40.
4. Hurwitz HI, et al. Clin Cancer Res. 2009 Jun 15;15(12):4220-7.
产品手册
关联产品
-
Tyrphostin AG1433
Tyrphostin AG1433 is an inhibitor of tyrosine kinases and also a dual inhibitor of PDGFRβ(IC50s = 5.0 μM) and VEGFR-2 (Flk-1/KDR)(IC50s = 9.3 μM).
-
BIBF 1202
BIBF 1202 is a VEGFR2 kinase inhibitor (IC50 = 62 nM).
-
Lariciresinol
Lariciresinol is an enterolignan precursor, it possesses fungicidal activities by disrupting the fungal plasma membrane and therapeutic potential as a novel antifungal agent for the treatment of fungal infectious diseases in humans. Dietary lariciresinol can attenuate mammary tumor growth and reduce blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats.